Development of the haloanilide, ELP-004 to prevent arthritis-induced bone erosion by inhibiting osteoclast differentiation

TECHNOLOGY SUMMARY

ELP-004 is a drug to treat rheumatoid arthritis by directly targeting the cells that cause the bone erosion instead immune components elevated in arthritis. ELP-004 is not immunosuppressive. ELP-004 is a small molecule that is easy and inexpensive to produce and is effective when administered orally.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech, Pharma, Health

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

Vetted Programs/Awards: We have a funded Small Business Technology Transfer grant from NIH (NIAMS) to develop this drug.

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Website: https://www.exesalibero-pharm.com

National Innovation Awardee

Showcase Booth #: M40, T40

MARKET KEYWORDS

Market Keywords: arthritis, oral administration, low cost